Osteoporosis, Postmenopausal Clinical Trial
Official title:
A 5-Year Long-term Follow-up Study of a Cross-Sectional Cohort Study (PK-VF) For the Examination of the Association of Vitamin D/Bone Turnover/Bone Mineral Density With an Incident Fracture in Chinese Postmenopausal Women
This proposed study was designed to investigate the prevalence of a 5-year incident osteoporotic fracture and evaluate the association of a 5-year change of 25-hydroxyvitamin D (25[OH]D)/bone turnover makers/bone mineral density (BMD) with the incident fracture in the Chinese postmenopausal women, based on an endeavor of a 5-year post-baseline follow-up visit of a previous cross-sectional study, PK-VF, in which 1724 participants were enrolled and examined.
1. In 2013, 5 years after PK-VF, the same 2070 subjects were contacted by the original
sites. Among them 1242 subjects were able to come for the follow-up assessment.
2. Clinical assessments: The participant's bio-information, physical examination and
medical history were collected;Questionnaire including social/life style and medical
evaluations (years since menopause (YSM), fracture history, milk/yoghourt/coffee/wine
intake, calcium intake, or smoking history) were collected by PK-VF investigators.
Non-vertebral fracture history evaluation: specific non-vertebral fracture sites
include rib or clavicle, forearm, upper arm, hand (including wrist), pelvis, hip, thigh
(not including hip), leg, and foot (including ankle). When non-vertebral fractures are
suspected, questions were raised to the participant to eliminate possible biases (How
did you get these fractures, a slight fall at home, fell from a high place, hit by
someone, broken during a car accident or an operation? Did you see a doctor to confirm
these fractures?) A fracture occurred in regular daily activities or due to mild trauma
was defined as fragile non-vertebral fracture.
3. Biochemical measurements: Fasting blood sample (~5 ml) was collected from each
participant at participating sites; In 2007-2008 study, blood samples were collected
during April-July, while in the 5-year follow-up; samples were collected in the same
period of time. C-terminal telopeptide of type I collagen (β-CTX), N-aminoterminal
prepeptide of type I procollagen (P1NP), and 25 (OH) D will be determined by a
laboratory method of electrochemiluminescence (E170; Roche Diagnostics, Basel,
Switzerland) in the institute (Peking Union); Chemistry including alkaline phosphatase
(ALP), calcium (Ca), creatinine (Cr), and glucose, will be measured by using automated
techniques in the institute (Peking Union);
4. BMD measurements: Lumbar spine (LS) and femoral neck (FN) BMDs by dual-energy x-ray
absorptiometry (DXA) (Lunar or Norland) at PK-VF sites. BMD calibration: The
participant's BMD were evaluated by the same type of DXA as previous. The coefficients
of variation of the seven hospitals were 0.75% to 1.7% for LS and 0.56% to 1.0% for FN.
Cross-calibration equations between machines are: LS BMD (g/cm2) Lunar = 1.012 ×
Norland + 0.0137 and, FN BMD (g/cm2) Lunar = 1.0377 × Norland + 0.00026
5. Vertebral fracture diagnosis: Lateral radiographs of the thoracolumbar spine (T4-L5)
were taken at PK-VF sites. Vertebral fractures will be assessed using Genant's
semi-quantitative visual criteria. Two specialist radiologists will independently
evaluate and diagnose vertebral fracture. A worsened existing vertebral fracture will
be regarded as a new vertebral fracture.
In 2007-2008 study, 2070 participants were recruited in this cohort, and 837 subjects (40%)
were diagnosed as osteoporosis. After 5 years, 1242 subjects agreed to be re-evaluated in
2013. Questionnaires and blood samples were collected, and BMD and spine x-ray were obtained
at the 5-year follow up. We estimate that around 625 subjects would be diagnosed as
osteoporosis. The remaining works include blood sample test (25(OH)D, CTX and P1NP),spine
x-ray films reading, data input and statistical analysis, paper writing and publication.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03931109 -
Circulating miRNA in Primary Hyperparathyroidism
|
||
Not yet recruiting |
NCT03232476 -
Effect of Mechanical Loading With PTH on Cortical Bone
|
Phase 4 | |
Completed |
NCT02884401 -
Peri-implant Bone Changes in Post-menopausal Osteoporotic Women
|
N/A | |
Completed |
NCT00073190 -
Patient- and Physician-Based Osteoporosis Education
|
Phase 1 | |
Completed |
NCT00402441 -
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
|
Phase 4 | |
Completed |
NCT03710889 -
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
|
Phase 3 | |
Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
Recruiting |
NCT05058976 -
Romosozumab Use to Build Skeletal Integrity
|
Phase 4 | |
Active, not recruiting |
NCT05405894 -
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
|
||
Recruiting |
NCT03337971 -
Nutritional Supplement and Bone Health in Post-Menopausal Women
|
N/A | |
Completed |
NCT03701113 -
Milk Protein and Bone Health in Postmenopausal Women
|
N/A | |
Completed |
NCT01381588 -
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
|
N/A | |
Completed |
NCT00383422 -
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
|
Phase 3 | |
Completed |
NCT00549965 -
Satisfaction and Compliance of Risedronate in PMO
|
Phase 4 | |
Completed |
NCT00035256 -
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
|
Phase 4 | |
Completed |
NCT01386281 -
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
|
||
Completed |
NCT05266261 -
Use of Ibandronate in Diabetic Patients
|
N/A | |
Recruiting |
NCT04964388 -
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
|
Phase 2 | |
Active, not recruiting |
NCT03623633 -
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
|
Phase 4 | |
Recruiting |
NCT05575167 -
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
|